Humoral and cellular responses after COVID-19 booster vaccination in patients recently treated with anti-CD20 antibodies

1

Patients treated with anti-CD20 antibodies show low seroconversion rates after COVID-19 vaccinations, particularly within 12 months of treatment.
2

A third booster dose of mRNA COVID-19 vaccines may improve humoral responses in patients with hematologic diseases when administered after longer intervals.
3

In this study, 42% of patients showed humoral responses after the third vaccination, compared to 15% before the booster.
4

T-cell responses increased from 30% before the booster to 51% after, indicating enhanced cellular immunity post-vaccination.
5

The study highlights the importance of timing in vaccination for patients on anti-CD20 therapy to achieve better immune responses.

Blood Cancer Journal

by Masashi Nishikubo, Yoshimitsu Shimomura, Ryusuke Yamamoto, Satoshi Yoshioka, Hayato Maruoka, Seiko Nasu, Tomomi Nishioka, Kenji Sakizono, Satoshi Mitsuyuki, Tomoyo Kubo, Naoki Okada, Daishi Nakagawa, Kimimori Kamijo, Hiroharu Imoto, Yuya Nagai, Nobuhiro Hiramoto, Noboru Yonetani, Tadakazu Kondo, Chisato Miyakoshi, Asako Doi, Takayuki Ishikawa
January 23, 2023

1